Apellis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:APLS)

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

14 brokerages have issued 1 year price objectives for Apellis Pharmaceuticals' shares. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's stock price to reach $66.50 in the next year. This suggests a possible upside of 41.0% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

Apellis Pharmaceuticals' stock was trading at $51.71 on January 1st, 2023. Since then, APLS shares have decreased by 8.8% and is now trading at $47.16.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our APLS earnings forecast.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Wednesday, November, 1st. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.88) by $0.29. The business had revenue of $110.40 million for the quarter, compared to the consensus estimate of $99.05 million. Apellis Pharmaceuticals had a negative net margin of 222.16% and a negative trailing twelve-month return on equity of 209.10%. The business's quarterly revenue was up 400.5% on a year-over-year basis. During the same period last year, the business earned ($1.75) EPS.

ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI).

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Apellis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (3.01%), FMR LLC (1.91%), Morgan Stanley (1.36%), Polar Capital Holdings Plc (0.89%), Assenagon Asset Management S.A. (0.87%) and Fiera Capital Corp (0.78%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends.

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.